Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | BID | P55957 | 3/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.44 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.44 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.44 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29571315 | 1.00 | CES2 (0.50) | CES2CES1GABRA1GABRB2BID | |
| SCHEMBL20505599 | 0.87 | BID (0.51) | CES2CES1BIDMCL1BCL2L1 | |
| SCHEMBL423306 | 0.85 | GABRA1 (0.54) | GABRA1GABRB2BIDMCL1BCL2L1 | |
| SCHEMBL14321505 | 0.84 | BID (0.60) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL1365718 | 0.83 | CES2 (0.45) | CES2CES1BIDMCL1BCL2L1 | |
| SCHEMBL14731241 | 0.82 | CES2 (0.48) | CES2CES1GABRA1GABRB2TDP1 | |
| SCHEMBL1364933 | 0.82 | DUSP3 (0.59) | CES2CES1TDP1ALBNPC1 | |
| Nitrogen SCHEMBL10979876 | 0.81 | GABRA1 (0.50) | GABRA1GABRB2BIDMCL1BCL2L1 | |
| SCHEMBL260553 | 0.80 | CES2 (0.67) | CES2CES1TDP1ALBNPC1 | |
| SCHEMBL23645663 | 0.80 | NLRP3 (0.47) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-107735401-B | Substituted dihydropyrrolopyrazole derivatives | 宇部兴产株式会社 | 2021-08-31 | — | — | CN | disclosed |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | disclosed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| EP-3309163-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016204153-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | 宇部興産株式会社 | 2016-12-22 | — | — | WO | disclosed |
| WO-2009073818-A1 | COMPOUNDS AND THERAPEUTIC USE THEREOF | MYRIAD GENETICS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-4910206-A | Endotoxin induced lung injury | SANDOZ PHARMACEUTICALS CORP. (US) | 1990-03-20 | — | — | US | disclosed |
| WO-1988006157-A1 | 5-HETERO- OR ARYL-SUBSTITUTED-IMIDAZO[2,1-a]ISOQUINOLINES | SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. (AT) | 1988-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | CES2 1231/4885CES1 1184/4885GABRA1 775/4885 |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | CES2 1231/4885CES1 1184/4885GABRA1 775/4885 |
| US-20230014445-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | CES2 2827/4885CES1 910/4885GABRA1 2867/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | CES2 1231/4885CES1 1184/4885GABRA1 775/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | CES2 1231/4885CES1 1184/4885GABRA1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.